On 2/20/25, Corcept Therapeutics Inc (NASDAQ: CORT) stock suffered a major decline of -11.5%, closing at $65.09. Moreover, exceptionally high trading volume at 227% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -4.4% during the last week.
Current PriceTarget Research Rating
Corcept Therapeutics has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Corcept Therapeutics has a poor Appreciation Score of 23 but a very high Power Rating of 95, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment